Search
ACE393
go.drugbank.com/drugs/DB05071InvestigationalACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.
Zamubafusp alfa
go.drugbank.com/drugs/DB32269InvestigationalZamubafusp alfa is an immunoglobulin-peptide fusion protein.[L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]
7,8-dihydrobiopterin
go.drugbank.com/drugs/DB04400Experimental7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalCirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
GEM-231
go.drugbank.com/drugs/DB05798InvestigationalA monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase.
ATG003
go.drugbank.com/drugs/DB05069InvestigationalATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
INKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
Namilumab
go.drugbank.com/drugs/DB13037InvestigationalNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
HEC-921
go.drugbank.com/drugs/DB33971ExperimentalHEC-921 is a biologic drug. … HEC-921 is under investigation in clinical trial NCT07824934 (HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors).